DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18–24 months old - Gunardi, Hartono; Rusmil, Kusnandi; Fadlyana, Eddy; Soedjatmiko; Dhamayanti, Meita; Sekartini, Rini; Tarigan, Rodman; Satari, Hindra Irawan; Medise, Bernie Endyarni; Sari, Rini Mulia; Bachtiar, Novilia Sjafri; Kartasasmita, Cissy B.; et al. (BMC pediatrics, 2018)
Keywords: Age; Antibody Formation - immunology; Antigens; Booster dose; Child; Child health; Children; Diphtheria; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects; Diphtheria-Tetanus-Pertussis Vaccine - immunology; Diphtheria-tetanus-pertussis vaccines; DTwP-HB-Hib vaccine; Edema - etiology; Female; Fever - etiology; Follow-Up Studies; Haemophilus Vaccines - administration & dosage; Haemophilus Vaccines - adverse effects; Haemophilus Vaccines - immunology; Health facilities; Hepatitis; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - adverse effects; Hepatitis B Vaccines - immunology; Humans; Immune response; Immunization, Secondary - adverse effects; Immunogenetics; Immunogenicity; Immunology; Infant; ISO standards; Laboratories; Male; Prospective Studies; Quality control; Safety; Safety and security measures; Tetanus; Vaccination - adverse effects; Vaccines; Whooping cough; Jakarta Indonesia; Japan; Indonesia; Booster dose; Children; Safety; Immunogenicity; DTwP-HB-Hib vaccine